Serotonin syndrome

  title={Serotonin syndrome},
  author={Russ A. Bodner and Timothy Lynch and Linda Lewis and David Kahn},
  pages={219 - 223}
Article abstract—We describe a patient treated with trazodone, isocarboxazid, and methylphenidate hydrochloride who developed confusion, agitation, poor concentration, rigidity, myoclonus, involuntary movements, orthostatic hypotension, and hyperreflexia. CK was normal, and the syndrome resolved spontaneously over 12 hours. The serotonin syndrome occurs following the use of serotomimetic agents (serotonin reuptake inhibitors, tricyclic and tetracyclic an-tidepressants, tryptophan, 3,4… 

Treatment of Serotonin Syndrome

  • S. Factor
  • Medicine, Psychology
    Current Clinical Neurology
  • 2019
The serotonin syndrome is a rare iatrogenic disorder cause by high dose or combinations of serotonergic agents. The most common combination today is paroxetine and tramadol. The features are motor,

Serotonin syndrome: a concise review of a toxic state.

The serotonin syndrome is a toxic state caused by increased intrasynaptic serotonin and characterized by a triad of altered mental status, autonomic instability and neuromuscular abnormalities that develops over a short period of time and resolves just as quickly once identified and treated.

Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia

A 45-year-old patient with a history of psychiatric illness who presented with severe hyperthermia with intense rhabdomyolysis and liver cytolysis during tetrabenazine therapy for neuroleptic tardive dyskinesia is observed.

Diagnosis of serotonin syndrome in the intensive care population: a case report

The patient in whom SS was suspected during ICU admission is presented, demonstrating the need to consider SS in the differential diagnosis of ICU patients with unexplained hyperthermia and signs of autonomic dysregulation, who are treated with serotonergic active medication.

Do bartonella infections cause agitation, panic disorder, and treatment-resistant depression?

The possibility that patients infected with Bartonella can have a variety of mental health symptoms is raised, without further information from epidemiology, microbiology, pathology, and treatment outcomes research.

Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline

It is concluded that selegiline's amphetamine-like metabolites may increase synaptic cathecholamines and possibly serotonin, aggravating fluoxetine’s effect and Rasagiline is devoid of this effect and may therefore be safer for use with serotonergic drugs in parkinsonian patients.

Identifying and managing psychiatric emergencies.

Diagnostic assessment of delirium includes thorough physical examination, careful cognitive testing, appropriate metabolic and infectious studies, review of medications, and structural brain imaging and electroencephalography as indicated.

Current status of symptomatic medical therapy in Parkinson’s disease

  • S. Factor
  • Medicine, Biology
  • 2011

Preclinical support for the therapeutic potential of zolmitriptan as a treatment for cocaine use disorders

It is suggested that zolmitriptan has potential for repurposing as a treatment for cocaine use disorders because it decreased cocaine intake at both cocaine doses and in both sexes even without a period of abstinence and without altering sucrose intake.

ADHD With Comorbid Bipolar Disorders: A Systematic Review of Neurobiological, Clinical And Pharmacological Aspects Across The Lifespan.

A systematic review of the scientific literature on the neurobiological, clinical features and current pharmacological management of ADHD comorbid with BDs across the entire lifespan, with a major focus on the adulthood.



Fluoxetine and side effects.

An increased risk of extrapyramidal signs and symptoms during treatment with fluoxetine or other potent and selective inhibitors of neuronal uptake of serotonin is reported, and the ability of serotonin uptake blockers to potentiate putative inhibitory effects of serotonin on the metabolic production or release of dopamine by neurons of the basal ganglia is predicted.

A case of MAO inhibitor/MDMA interaction: agony after ecstasy.

This case suggests that MDMA can cause significant toxicity in patients taking MAO inhibitors, and shares structural and pharmacologic features with other agents capable of causing this interaction.

Adverse consequences of fluoxetine-MAOI combination therapy.

The authors describe two series of patients: 12 treated simultaneously with fluoxetine and a monoamine oxidase inhibitor and 6 patients started on treatment with an MAOI 10 days or more after

Current concepts. Neuroleptic malignant syndrome.

Neuroleptic drugs are used extensively in the treatment of psychotic illnesses and are widely employed in general medicine as antiemetics, for dissociative anesthesia, and to treat diseases such as Tourette's syndrome.

Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor

When similar doses of tryptophan were administered to patients undergoing treatment with a potent inhibitor of monoamine oxidase (MAO), definite neurologic alterations occurred and their relationship to alterations in the metabolism oftryptamine and 5-hydroxytryptamine (serotonin).

Fluoxetine and neuroleptic malignant syndrome

Usefulness of Fluoxetine Hydrochloride for Prevention of Resistant Upright Tilt Induced Syncope

It is concluded that fluoxetine may be an effective therapy in patients with recurrent vasovagally mediated syncope refractory to other forms of therapy.

Myoclonus, Hyperreflexia and Diaphoresis in Patients on Phenelzine-Tryptophan Combination Treatment

Three cases are presented on patients on an MAOI who developed a transient syndrome of myoclonus, hyperreflexia, jaw quivering, teeth chattering and diaphoresis after L-Tryptophan was added. Caution